Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
PDS Biotechnology logo — company profile

PDS Biotechnology

Founded 2005 United States Princeton, United States 31 employees Post Ipo Debt Total: $57.04M Biotechnology, Health Care +1

General Information

Company Name PDS Biotechnology
Founded Year 2005
Location United States Princeton, United States +1
Employees 31
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Debt
Social

Get notified when PDS Biotechnology moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About PDS Biotechnology

PDS Biotechnology is a biopharmaceutical company based in North Brunswick, New Jersey. Since its establishment in 2005, the company has been dedicated to developing immunotherapies for cancer and infectious diseases. Their product range encompasses treatments for various types of cancers including cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. Notable offerings from PDS Biotechnology Corporation include PDS0101 for HPV-related cancers, PDS0102 for pandemic influenza, and PDS0103 for non-viral cancers. The company received a $25.00M Post-IPO Debt investment on 24 August 2022 from Horizon Technology Finance.

Overall, PDS Biotechnology Corporation displays promising potential within the biotechnology, health care, and pharmaceutical industries. With a focus on addressing unmet medical needs through innovative immunotherapies, the company has attracted substantial investment, highlighting investor confidence in its development pipeline. PDS Biotechnology's dedication to combatting a wide range of cancers and infectious diseases positions it as an impactful player in the biopharmaceutical space. The recent $25.00M investment is a testament to the industry's belief in the company's capabilities. As the company continues to advance its product offerings and clinical developments, it remains one to watch for potential future growth and impact within the healthcare sector.

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt •••••• 1
Investor
24 Aug 2022
Post-IPO Equity •••••• - 13 Aug 2020
Post-IPO Equity •••••• - 14 Feb 2020
Post-IPO Equity •••••• - 29 Sep 2016
Post-IPO Debt •••••• - 26 Aug 2016

PDS Biotechnology Alternatives & Competitors

PDS Biotechnology vs
Alberta Insurance Council
Alberta Insurance Council Canada

The AIC serves to fulfill the mission of protecting Albertans through the licensing and regulation o...

68 employees
Financial Services, Insurance
Compare PDS Biotechnology vs Alberta Insurance Council
PDS Biotechnology vs
German Orient-Institute
German Orient-Institute Germany

The oldest private scientific research institute on the Near and Middle East in Europe (founded by N...

4 employees
Social Media
Compare PDS Biotechnology vs German Orient-Institute
PDS Biotechnology vs
Gwich'in Tribal Council
Gwich'in Tribal Council Canada

Gwich'in land, culture, and economy for a better future.

Grant
34 employees
Government and Military, Social Media
Compare PDS Biotechnology vs Gwich'in Tribal Council

FAQ About PDS Biotechnology

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body's immune system in the fight against cancer and infectious disease.
PDS Biotechnology was founded in 2005.
PDS Biotechnology is headquartered in Princeton, United States.
PDS Biotechnology operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
PDS Biotechnology has approximately 31 employees.
PDS Biotechnology has completed 5 funding rounds, raising a total of $57.04M. The latest funding stage is Post Ipo Debt.
Top alternatives and competitors to PDS Biotechnology include Alberta Insurance Council, German Orient-Institute, Gwich'in Tribal Council, Goshen Public Library and Historical Society, Greek Orthodox Archdiocese of America. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PDS Biotechnology and Alberta Insurance Council are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors PDS Biotechnology and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy